Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 By webadmin@biolojic.com|2024-06-25T13:25:24+00:00June 12, 2024|News|0 Comments Read More
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany. By webadmin@biolojic.com|2024-06-05T12:40:50+00:00June 5, 2024|News|0 Comments Read More
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases By webadmin@biolojic.com|2024-06-05T12:40:33+00:00April 24, 2024|News|0 Comments Read More